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In this paper we utilize methods of hyperdimensional computing to mediate the identiﬁcation of thera-
peutically useful connections for the purpose of literature-based discovery. Our approach, named Predi-
cation-based Semantic Indexing, is utilized to identify empirically sequences of relationships known as
‘‘discovery patterns’’, such as ‘‘drug x INHIBITS substance y, substance y CAUSES disease z’’ that link phar-
maceutical substances to diseases they are known to treat. These sequences are derived from semantic
predications extracted from the biomedical literature by the SemRep system, and subsequently utilized
to direct the search for known treatments for a held out set of diseases. Rapid and efﬁcient inference is
accomplished through the application of geometric operators in PSI space, allowing for both the deriva-
tion of discovery patterns from a large set of known TREATS relationships, and the application of these
discovered patterns to constrain search for therapeutic relationships at scale. Our results include the
rediscovery of discovery patterns that have been constructed manually by other authors in previous
research, as well as the discovery of a set of previously unrecognized patterns. The application of these
patterns to direct search through PSI space results in better recovery of therapeutic relationships than
is accomplished with models based on distributional statistics alone. These results demonstrate the util-
ity of efﬁcient approximate inference in geometric space as a means to identify therapeutic relationships,
suggesting a role of these methods in drug repurposing efforts. In addition, the results provide strong sup-
port for the utility of the discovery pattern approach pioneered by Hristovski and his colleagues.
 2012 Elsevier Inc. All rights reserved.1. Introduction
This paper addresses the role of representation in the repurpos-
ing of pre-existing biomedical knowledge to identify novel thera-
peutic strategies. On account of the large number of possibly
useful undiscovered connections between drugs and the diseases
they treat, some work in literature-based discovery (LBD) has
emphasized scalable methods based on the distributional statistics
of terms or concepts in the literature. An advantage of many of
these methods is the facility for efﬁcient search to identify associ-
ations between terms and/or concepts that do not co-occur with
one another in the literature, based on similarity between their
vector representations, which are derived from their distributional
statistics. However, as economic constraints limit the number of
potential therapies that can be advanced for further testing, more
stringent constraints based on the nature of the relationships be-
tween concepts are desirable. Recent work in LBD has introducedll rights reserved.
ical Informatics, University of
States.
en).the notion of a discovery pattern [1–4], a pathway of logical connec-
tions between concepts that suggests a potentially therapeutic
relationship. Up to this point, researchers have designed discovery
patterns manually, by composing sequences of relationship types,
such as ‘‘drug x INHIBITS substance y, substance y CAUSES disease
z’’, that suggest therapeutic potential. In addition, as these patterns
are represented computationally as sequences of symbols, it is nec-
essary to explore possible pathways in a stepwise manner, in con-
trast to the efﬁcient search facilitated by the representation of
terms or concepts in a vector space. In this paper we address these
issues by representing both concepts and the relationships be-
tween them as vectors in hyperdimensional space, using the Pred-
ication-based Semantic Indexing (PSI) approach [5].
The paper proceeds as follows. First we discuss LBD research,
with an emphasis on recent approaches that have been facilitated
by advances in biomedical language processing, and introduce
SemRep [6], the language processing system we have utilized for
this research. We then introduce PSI [5], a representational ap-
proach we have developed that facilitates approximate inference
across large volumes of knowledge extracted by SemRep, using a
geometric approach. This background material is followed by a
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our approach to inference in PSI space. We then proceed to a study,
in which we identify discovery patterns from a set of known
TREATS relationships, and an experiment in which we apply these
‘‘discovered’’ discovery patterns to a held out set of diseases. The
aim of this experiment is to evaluate our hypothesis that directing
search using the identiﬁed discovery patterns will improve the
recovery of treatments for members of this held out disease set,
when compared with a co-occurrence based approach. The results
and implications of this empirical work are subsequently
discussed.
2. Background
2.1. Literature-based discovery
The ﬁeld of literature-based discovery traces its origins to a ser-
endipitous discovery of a therapeutically useful [7] connection be-
tween ﬁsh oils and Raynaud’s disease by information scientist Don
Swanson [8]. This discovery was made by ﬁnding points of inter-
section between two bodies of literature that were disconnected
from one another with respect to authorship and readership.
Swanson identiﬁed bridging concepts such as blood viscosity that
could be used to connect Raynaud’s to concepts that had not oc-
curred with it in the literature previously. This approach has been
generalized and applied to a number of other problems (for recent
reviews see [9–11]). The general idea is to use a bridging, or B con-
cept, to link two other concepts, usually referred to as A and C, that
have not co-occurred in the literature previously. This scheme al-
lows for two modes of discovery, termed open and closed (5). Open
discovery has two steps. Starting with a disease C, a set of interme-
diate B concepts is identiﬁed in literature related to this disease.
The literature on these B (or ‘‘bridging’’) concepts is then explored
to seek out A concepts, potential treatments. In closed discovery,
the starting point is the hypothesis, or observation, of a therapeutic
relationship between treatment A and disease C (AC), and an expla-
nation (AB, BC) for this observation or hypothesis is sought by
exploring the literature for concepts related to both A and C. Swan-
son’s approach has also been incorporated into a number of auto-
mated systems that aim to promote discovery by encouraging
scientists to search beyond the limits of their usual literature re-
view (for example [12–16], and for a review see [17]).
Swanson’s initial work was motivated primarily by the increas-
ingly disjointed nature of the scientiﬁc literature that is an inevita-
ble consequence of increased specialization. As noted by Swanson
[18], the rapid increase in the volume of the biomedical literature
is accompanied by a combinatorial explosion in the number of im-
plicit connections between entities described in this literature [19].
Consequently, a scalable alternative to stepwise exploration of
every possible pathway from disease to discovery is desirable.
To this end, several LBD researchers have investigated the use of
methods of distributional semantics [20] as a means to identify di-
rectly associations between terms or concepts that do not co-occur
with one another in the biomedical literature [21–23]. Methods of
distributional semantics learn measures of relatedness between
terms or concepts from their distribution across large volumes of
electronic text. With some distributional approaches, terms or con-
cepts that occur in similar contexts will be strongly associated,
even if they do not appear together directly. Therefore, search
can proceed directly from A to C, without the need to explicitly
identify a B concept. This, and the reduced-dimensional nature of
the representations employed in distributional models, allow for
efﬁcient search for previously unrecognized meaningful relations.
In our previous work we have shown that distributional ap-
proaches can be used to simulate historical literature-based dis-
coveries, and predict terms that will co-occur with one anotherin the future from a time-delimited training set [23]. However, as
they are based on occurrence in the context of similar surrounding
words or concepts, the associations learned by these models tend
to be general in nature. Given the vastness of the search space
for possible discoveries, further representational richness is re-
quired to identify selectively candidates for discovery in which
the nature of the relationships between concepts suggest a plausi-
ble therapeutic hypothesis. It is possible to extract this additional
information from the biomedical literature using specialized natu-
ral language processing systems such as SemRep [6].
2.2. SemRep
SemRep is a symbolic natural language processing system that
identiﬁes semantic predications in biomedical text. For example,
SemRep extracts ‘‘Acetylcholine STIMULATES Nitric Oxide’’ from
the sentence ‘‘In humans, ACh evoked a dose-dependent increase
ofNO levels in exhaledair’’. SemRep is linguisticallybasedand inten-
sively depends on structured biomedical domain knowledge in the
UniﬁedMedical Language System (UMLS SPECIALIST Lexicon,Meta-
thesaurus, Semantic Network [24]). At the core of SemRep process-
ing is a partial syntactic analysis in which simple noun phrases are
enhanced with Metathesaurus concepts. Rules ﬁrst link syntactic
elements (such as verbs and nominalizations) to ontological predi-
cates in the Semantic Network and then ﬁnd syntactically allowable
noun phrases to serve as arguments. A metarule relies on semantic
classes associated withMetathesaurus concepts to ensure that con-
straints enforced by the Semantic Network are satisﬁed.
SemRep provides underspeciﬁed interpretation for a range of
syntactic structures rather than detailed representation for a lim-
ited number of phenomena. Thirty core predications in clinical
medicine, genetic etiology of disease, pharmacogenomics, and
molecular biology are retrieved. Quantiﬁcation, tense and modal-
ity, and predicates taking predicational arguments are not ad-
dressed. The application has been used to extract 23,751,028
predication tokens from 6,964,326 MEDLINE citations (with dates
between 01/10/1999 and 03/31/2010). Several evaluations of Sem-
Rep are reported in the literature. For example, in [25] .73 precision
and .55 recall (.63 f-score) resulted from a reference standard of
850 predications in 300 sentences randomly selected from MED-
LINE citations. Kilicoglu et al. report .75 precision and .64 recall
(.69 f-score) based on 569 predications annotated in 300 sentences
from 239 MEDLINE citations [26]. Recent research in literature-
based discovery [1–4] has exploited the additional information
provided by specialized language processing systems such as Sem-
Rep by developing the idea of a discovery pattern.
2.3. Discovery patterns
Swanson’s description of his own approach presupposes the
representation of the nature of the relationships that occur be-
tween concepts (emphasis added):
Suppose that one literature reports that, under certain circum-
stances, A causes B (e.g., drug A alters blood levels of hormone
B). Such a causal statement is denoted by ‘‘AB.’’ Assume that a sec-
ond literature reports a similar causal connection, BC (e.g., hor-
mone B inﬂuences the course of disease (C). Presumably, then,
anyone aware of the two premises AB and BC would notice that
A might inﬂuence C (denoted ‘‘AC’’)
– Swanson 1990
However, approaches based on co-occurrence alone do not offer
the representational richness required to populate a syllogistic
construction of this nature. In recognition of the limitations of
co-occurrence based approaches, Hristovski and his colleagues
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(object-relation-object triplets) that might suggest plausible thera-
peutic hypotheses [1–4]. The extraction of predications from the
biomedical literature is accomplished through the application of
natural language processing technology, speciﬁcally the SemRep
[6] and MedLEE [27] systems for biomedical language processing.
As an example of a discovery pattern, consider the ‘‘may_dis-
rupt’’ pattern, as deﬁned by Ahlers and her colleagues [4]:
Substance X <inhibits> Substance Y;
Substance Y <causes|predisposes|associated_with> Pathology Z;
Substance X <may_disrupt> Pathology Z
This pattern is represented using the following set of relation-
ship types (or predicates) extracted by SemRep: {INHIBITS,
CAUSES, PREDISPOSES, ASSOCIATED_WITH}, with the aim to iden-
tify explanatory hypotheses for the observation that schizophrenic
patients, who are often treated with anti-psychotic agents, have
lower incidences of cancer than the general population [4]. Other
discovery patterns have been used to simulate Swanson’s original
discovery [1], and to suggest therapeutic hypotheses for Parkin-
son’s disease by combining predications derived from the litera-
ture with others derived from DNA micro-array results [3]. Up to
this point, researchers, based on their domain knowledge and their
interpretation of what might construe a meaningful explanatory
pathway, have constructed discovery patterns manually, and ap-
plied them by traversing the network of concepts and relations
on a node-by-node basis.
Consider the ‘‘may_disrupt’’ pattern from the perspective of a re-
searcher searching for a novel treatment for a particular pathology.
Exhaustive exploration of all possible therapies for this pathology
according to this pattern requires retrieving all concepts that occur
as the subjects of a CAUSES, ASSOCIATED WITH or PREDISPOSES
relationship with it, or any variant forms of interest (for example,
Ahlers and her colleagues took any concept of the UMLS type
‘‘neop’’ or neoplastic process as their set of ‘‘Z’’ pathologies). Subse-
quently, any concept occurring as the subject of an INHIBITS rela-
tionship with any of these retrieved concepts must be explored.
Therefore, the size of the search space in this case is the product
of the number of concepts describing the disease in question, all
of which must be explored to seek relevant predicates, multiplied
by the number of unique predications involving any of these con-
cepts and the predicates CAUSES, ASSOCIATED_WITH or PREDIS-
POSES, multiplied in turn by the number of the subjects of these
predications that occur in predications with the predicate INHIB-
ITS. As anticipated by Swanson, a combinatorial explosion in the
size of this search space would occur if more than one bridging
term were considered.
In practice, Ahlers and her colleagues took a closed discovery
approach, enabling them to triangulate from starting points includ-
ing both neoplastic processes and a number of selected antipsy-
chotic agents. The number of predications in the search space
was also limited to those extracted from related PubMed queries,
as was the case in other LBD work in which discovery patterns
were utilized [1,2]. However, as anticipated by Swanson, the
ever-increasing numbers of logical connections between biomedi-
cal concepts limit the computational tractability of exhaustive
search across the breadth of the biomedical literature for the pur-
pose of either open or closed discovery.
2.4. Predication-based Semantic Indexing
The extent to which inference can be accomplished is con-
strained by the way in which knowledge is represented. A common
strategy for re-use of the biomedical literature is to draw
associations between concepts (or terms) occurring in similar con-texts [21–23]. This leads to a measure of general relatedness that is
convenient to derive, but limited in its speciﬁcity. Another strategy
involves representation of concepts, and the relations between
them, as symbols [1,2]. This allows search to be directed precisely,
but requires node-by-node exploration of the network of concepts
and relations. Our approach, which is based on the hyperdimen-
sional computing paradigm [28], combines the strengths of both
of these strategies. Both concepts and the relationships between
them are represented as vectors in hyperdimensional space. Infer-
ence occurs as a function of the geometry of this space, mediated
by reversible vector transformations. This approach, which we
have named Predication-based Semantic Indexing [5] (PSI), inte-
grates algebraic and geometric models of intelligence to support
scalable search [29] and efﬁcient inference [30] across large vol-
umes of computable knowledge, providing a computationally trac-
table means to generate therapeutic hypotheses.
2.5. Mathematical structure and methods
2.5.1. Vector symbolic architectures
PSI adopts the Random Indexing approach as described in [23],
in which a semantic vector for a concept is generated by superpos-
ing randomly constructed elemental vectors representing the con-
texts in which this concept occurs. These vectors may be binary,
real or complex in nature. However, regardless of this representa-
tional choice, it is important that elemental vectors be constructed
such that they are unlikely to be similar to one another. This con-
straint is important, as it ensures that an elemental vector provides
a unique signature for the entity it is encoding, so that this entity
can be correctly re-identiﬁed despite any distortions of the original
elemental vector that may occur during the learning process. Vec-
tors utilized in this approach are of high dimensionality (in the
thousands or tens of thousands), and the combination of this high
dimensionality and the construction of dissimilar elemental vec-
tors makes the representation robust.
Semantic vectors can be thought of as containers for knowledge
encoded by elemental vectors. Throughout this paper we will write
E(X) and S(X) for the elemental and semantic vectors associated
with the concept X. In addition, we introduce elemental vectors
for relations, such that E(R) denotes the elemental vector for the
relation R. As many relations are directional, we will use RINV to de-
note the inverse of R, such that A R B (e.g. thalidomide TREATS mul-
tiple myeloma) and B RINV A (e.g. multiple myeloma ‘‘TREATSINV’’ =
‘‘IS TREATED BY’’ thalidomide) carry the same meaning, though
they may be encoded by different vector representations.
To encode relations, PSI utilizes the hyperdimensional comput-
ing paradigm [28] exempliﬁed by the models of Kanerva [31] and
others [32–34] that are collectively known as Vector Symbolic
Architectures (VSAs) [33]. VSAs are descendants of Smolensky’s
tensor-product based connectionist approach [35] to encoding
symbolic knowledge and nested compositional structure. Relations
are encoded in these models using reversible vector transforma-
tions, a process referred to as binding.
Binding is a multiplication-like operator through which two
vectors are combined to form a third vector C that ismaximally dis-
similar from either of its component vectors, A and B. We will use
the symbol ‘‘’’ for binding, and the symbol ‘‘’’ for the inverse of
binding throughout this paper. It is important that this operator be
invertible, in order to facilitate the recovery (or release) of informa-
tion encoded into a bound product. Consequently, if C = A  B, then
A C = A (A  B) = B. Under some circumstances this recovery
will be approximate, but the robust nature of the underlying
hyperdimensional vector representation ensures that A C will
be sufﬁciently similar to B that the original vector for B can be rec-
ognized as the best matching candidate for A C in the original
set of concepts.
Table 1
Inferring the connections between multiple myeloma and thalidomide. 1-HD = 1-
(normalized Hamming distance); SD > random = number of Standard Deviations
above mean (1-HD) between random vectors.
Paired predicate 1-HD SD > random
ASSOCIATED_WITH; COEXISTS_WITH 0.5158 5.653
INHIBITS; ASSOCIATED_WITH 0.5154 5.510
INTERACTS_WITH; ASSOCIATED_WITH 0.5123 4.401
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and that the symbol ‘‘’’ should not be identiﬁed with the tensor
product. For example, Plate’s Holographic Reduced Representa-
tions use circular convolution of real or complex vectors [32], while
Kanerva’s Binary Spatter Code (BSC) [31], which we utilize in our
experiments, uses bitwise exclusive or (XOR) and binary vectors.
In this case, the binding operator is its own inverse ( and 
are the same operator, namely XOR), but we will nonetheless use
different symbols to represent these operators to maintain consis-
tency with VSAs in general. In addition to being invertible, the
binding operators used in VSAs all produce a bound product of
the same dimensionality as the component vectors from which it
was derived. This distinguishes VSAs from earlier models using
tensor products, which resulted in a bound product with the
dimensionality of its components vectors squared. Of note, using
bitwise XOR to implement binding for binary vectors implies that
in this case, binding commutes: A  B = B  A.
Bundling is an addition-like operator, through which superposi-
tion of vectors is achieved. Unlike binding, bundling produces a vec-
tor that ismaximally similar to the component vectors fromwhich it
was derived. One example of a bundling operator is the use of vec-
tor addition and subsequent normalization. Another is the majority
rule used in the BSC, where each dimension of the vector resulting
from the superposition is assigned either ‘‘1’’ or ‘‘0’’ in accordance
with the most popular value in this dimension in the component
vectors, with ties broken at random. We will use the symbol ‘‘+’’
to denote bundling, and the computer science ‘‘+=’’ for ‘‘bundle
the left hand side with the right hand side, and assign the outcome
to the symbol on the left hand side’’. So, for example S(A) + = E(B)
denotes the addition of the elemental vector for B to the semantic
vector representing A, a common operation in training.
2.5.2. Predication-based Semantic Indexing
PSI combines the binding and bundling operators to encode
predications during the training process. For example, the predica-
tion ‘‘thalidomide INHIBITS cyclooxygenase 2’’ is encoded by the
following sequence of steps:
SðthalidomideÞþ ¼ EðINHIBITSÞ  Eðcyclooxygenase2Þ
Sðcyclooxygenase2Þþ ¼ EðINHIBITSINVÞ  EðthalidomideÞ
Similarly, the predication ‘‘cyclooxygenase 2 ASSOCIATED WITH
multiple myeloma is encoded as follows:
SðmutiplemyelomaÞþ¼EðASSOCIATEDWITHÞEðcyclooxygenase 2Þ
Sðcyclooxygenase 2Þþ¼EðASSOCIATEDWITHÞEðmultiplemyelomaÞ
Note that in the case of ASSOCIATED_WITH, we have not used an in-
verse, as this relationship is not directional. In practice, statistical
weighting and frequency thresholds are used to limit the inﬂuence
of uninformative predications, as will be discussed further in the
methods section. The net result is a hyperdimensional vector space,
with dimensionality predetermined by the size of the pre-assigned
elemental vectors. A vector that captures, albeit approximately, the
predications this concept has occurred in, represents each concept.
2.5.3. Statistical properties of hyperdimensional binary space
While we have presented the operations underlying our ap-
proach such that they will be compatible with VSAs in general,
for the research described in this paper we utilized Kanerva’s Bin-
ary Spatter Code[31] (BSC). The BSC uses hyperdimensional (e.g.
dimensionality P10,000) binary vectors as a representation for
concepts and relations (or variables). Elemental vectors are ran-
domly generated such that every dimension in the vector has an
equal probability of being one or zero, and there are an equal num-
ber of ones and zeros in each vector. As noted by Kanerva [36], this
leads to some useful statistical properties.As there is a 50% probability of a one or zero occurring in each
dimension, the mean Hamming distance between any two ran-
domly constructed vectors will be a half of the dimensionality of
the vectors. For example, in a 10,000 dimensional space we would
anticipate elemental vectors being 5000 bits apart from one an-
other on average. In hyperdimensional binary space, this distance
is referred to as the indifference distance, and two points at this dis-
tance from one another are considered to be orthogonal to one an-
other [36]. Secondly, the standard deviation of this distribution of
Hamming distances is a half of the square root of the dimensional-
ity of the vectors. To continue our example, we would anticipate a
standard deviation of 50 in a 10,000-dimensional space. A conse-
quence of this distribution is that an elemental vector has a high
probability of being far apart from every other elemental vector.
This sparseness of the space confers robustness, as it implies that
it is possible to distort an elemental vector considerably, while
retaining conﬁdence that it will be closer to its original form than
to any other elemental vector in the space.
2.5.4. Inference in PSI space
2.5.4.1. Inferring predicate pathways. PSI provides the means to
facilitate two sorts of inference. Firstly, it is possible to infer from
two semantic vectors the dual-predicate pathway through which
they are connected. Consider the following steps that occurred
during the training process:
SðthalidomideÞþ ¼ EðINHIBITSÞ  Eðcyclooxygenase 2Þ
Sðmultiple myelomaÞþ ¼ EðASSOCIATED WITHÞ
Eðcyclooxygenase 2Þ
As both S(thalidomide) and S(multiple_myeloma) now contain
E(cox_2) (cyclooxygenase 2 is abbreviated as cox_2), applying the
inverse of the binding operator,, will result in this common con-
cept cancelling out, such that:
SðthalidomideÞ Sðmultiple myelomaÞ
 EðINHIBITSÞ  Eðcox 2Þ Eðcox 2Þ EðASSOCIATED WITHÞ
 EðINHIBITSÞ EðASSOCIATED WITHÞ
The resulting vector will be a noisy approximation of the elemental
vectors concerned, but in hyperdimensional space it is highly prob-
able that this approximation will be signiﬁcantly closer to these ele-
mental vectors than to any other vector in the space [28]. In some
cases, the resulting predicate pathway provides a plausible explan-
atory hypothesis. For example, it is plausible that thalidomide’s
therapeutic effect in multiple myeloma may be related to inhibition
of cox-2. As further examples, in one of the PSI spaces utilized for
our experiments, the three closest bound pairs of predicate vectors
to the vector produced by this operation are shown in Table 1.
Note that the relatedness between these pathways and the vec-
tor SðthalidomideÞSðmultiple myelomaÞwas signiﬁcantly higher
than that of the next-nearest neighboring vector, which was only
3.31 SD above the mean anticipated between random vectors.
2.5.4.2. Generalizing to new diseases. As we have shown previously
[30], an inferred predicate pathway can be applied to other
semantic vectors to direct search across predicate paths of interest.
Fig. 1. Overview of the Evaluation.
Fig. 2. Generation of explanatory hypotheses.
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EðASSOCIATED WITHÞ or the approximation of this vector inferred
from SðthalidomideÞ Sðmultiple myelomaÞ, can be used to direct
search through PSI space for concepts that relate to some other con-
cept in the samemanner as theﬁrst twoconceptswere related toone
another. For example, consider the following composite cue vectors:
Sðmalignant mesotheliomaÞ EðASSOCIATED WITHÞEðINHIBITSÞ
Sðmalignant mesotheliomaÞ Sðmultiple myelomaÞ SðthalidomideÞ
Either of these composite cue vectors can be used to direct search
toward semantic vectors representing concepts that relate to malig-
nant mesothelioma in the same manner that thalidomide is related
to multiple myeloma, effectively solving the proportional analogy
problem ‘‘what is to malignant mesothelioma as thalidomide is to
multiple myeloma?’’ When the second approach is used, accuracy
depends on the contribution that the relevant predicate pathways
make to the vector representations of the component semantic vec-
tors, which are likely to also encode other, unrelated, predicate-
argument pairs.
These approaches provide the means to implement discovery
patterns at scale, as novel relationships between A and C concepts
are identiﬁed directly, without the need to explicitly traverse
bridging B concepts. In the section that follows, we present an eval-
uation of the utility of this approach as a means to identify thera-
peutic relationships. We do so using the sequence of inference
procedures we have just described: ﬁrst we infer explanatory path-
ways from pharmaceutical agents to diseases they are known to
treat, and then we generalize to another held out set of diseases,
to attempt to identify pharmaceutical agents that treat them.
3. Evaluation
3.1. Overview
Fig. 1 provides an overview of the research described in this pa-
per. To evaluate the ability of our methods to support discovery, we
conduct a study (Fig. 1, left, described in Section 3.2) followed by an
experiment (Fig. 1, right, described in Section 3.3). In the ﬁrst of
these, we generate a PSI space (PSI space 1) without encoding
any TREATS relationships, and infer the most strongly associated
dual-predicate path between all pharmaceutical substances (UMLS
semantic type ‘‘phsu’’) and diseases or syndromes (UMLS semantic
type ‘‘dsyn’’) that occur together in a TREATS relationship
(n = 48,204) in the SemRep database. In the second, we utilize the
5-to-10 most popular inferred paths to direct search through pred-
ication space. This search occurs in the context of a PSI space (PSI
space 2) in which no direct relationships of any kind between phar-
maceutical substances and neoplastic processes (UMLS semantic
type ‘‘neop’’) are encoded. We evaluate the extent to which the dis-
covered discovery patterns can be used to ‘‘rediscover’’ TREATS
relationships involving pharmaceutical substances and neoplastic
processes in the SemRep database, and compare this to the perfor-
mance of a distributional approach, Reﬂective Random Indexing
[23], that derives an estimate of the relatedness between concepts
from their distributional statistics in a corpus of documents.
Our hypothesis is that directed search using the discovery pat-
terns identiﬁed during the initial study (using PSI) will be more
productive than search using general association between con-
cepts, without considering the nature of the relationships con-
cerned (using RRI).
3.2. Generating explanatory hypotheses
In this study, we infer the most popular dual-predicate paths
between diseases or syndromes and pharmaceutical substancesthat occur together in TREATS relationships in the SemRep data-
base (n = 48,204). The study is conducted in the context of a PSI
space that is ignorant of all TREATS relations so as to eliminate
the possibility of indirect treats relationships being inferred from
direct treats relationships (for example, it may be inferred that
one drug that has been compared with another that is known to
treat diabetes, would also treat diabetes).
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An overview of the study is presented in Fig. 2. The predications
extracted by SemRep from a set of 8,182,882 MEDLINE citations
dated between 1999 and 2011 (n = 21,720,623) were divided into
TREATS predications (n = 1,592,143), and other predications
(n = 20,128,480). The TREATS pairs were kept aside, and from these
a set of unique predications of the form ‘‘phsu TREATS dsyn’’ where
phsu represents the UMLS semantic type ‘‘pharmaceutical sub-
stance’’, and dsyn represents the UMLS semantic type ‘‘disease or
syndrome’’ were extracted (n = 48,204). All other predications of
the permitted predicate types, deﬁned by the set {ASSOCI-
ATED_WITH; COEXISTS_WITH; AFFECTS; AUGMENTS; CAUSES;
DISRUPTS; INHIBITS; INTERACTS_WITH; PREDISPOSES; STIMU-
LATES} were used to generate a PSI space. All concepts occurring
100,000 times or more were excluded from the space, to eliminate
frequently occurring concepts that carry little information content.
Only those dsyn-phsu pairs in which both elements were repre-
sented in the PSI space were retained (n = 43,954).
Training occurred as follows. Every concept Cn was assigned a
semantic vector S(Cn). Every concept Cn was also assigned an ele-
mental vector E(Cn). Elemental vectors for this study were
32,000-dimensional binary vectors, with 16,000 1s and 16,000 0s
distributed at random across the vector. To maintain consistency
across experiments, we seeded our random number generator with
a hash function derived from the name of the concept-to-be-repre-
sented, as described in [37]. Therefore, the ‘‘random’’ vectors in this
case are in fact deterministic, so the incidental overlap between
vectors was consistent across experiments. Each predicate, Pm, is
also assigned an elemental vector, E(Pm). For each unique predica-
tion that a given concept Ca occurred in, training for this concept
occurred as follows:
SðCaÞþ ¼ EðCbÞ  EðPcÞ  lw gw
where Cb and Pc are the other concept and the predicate in the pred-
ication respectively, and lw and gw are local and global weighting
metrics respectively, deﬁned as follows:
lw ¼ logð1þ global frequency of predicationÞ
gw ¼ idf ðPcÞ þ idf ðCbÞ
idf ¼ log number documents in corpusnumber documents containing predicate=argument
Consequently the weight of the contribution of a predicate-argu-
ment pair is equal to the log of one plus the frequency with which
this predication occurs, multiplied by the sum of inverse document
frequencies (idf) of the concept and the relation concerned. These
statistical weighting metrics were utilized to enhance the inﬂuence
of infrequently occurring concepts and relations. As we were gener-
ating semantic vector representations for both concepts, the com-
plementary encoding also occurred:
SðCbÞþ ¼ EðCaÞ  EðPcINV Þ  lw gw
In this instance we have used the inverse of the predicate Pc, PcINV, to
encode the directionof the relationship concerned.However, in some
cases, such as the predicate ‘‘COEXISTS_WITH’’, the relationship is
not directed, and so a single predicate vector is used (Pc = PcINV). Once
training was complete, a search space of possible dual-predicate
paths was constructed by combining the elemental vectors for each
permitted predicate type (n = 17, when allowing for inverse relations
with some predicate types) using the following procedure:
For each predicate p1
For every other predicate p2
Sðpredicate pathÞ ¼ Eðp1Þ Eðp2ÞOnce this search space of predicate paths was constructed, infer-
ence was performed by generating a composite cue vector from
the semantic vectors of each of the 43,954 phsu–dsyn pairs. This
was accomplished using the following procedure:
cuevector ¼ SðphsuÞ SðdsynÞ
This search was performed for all of the phsu–dsyn pairs, and in
each case the most strongly associated dual-predicate pathway
was retained. Each of the possible pathways was ranked according
to the number of times it was most strongly associated with an
example. Inference is computationally efﬁcient (scaling at a rate
linear to the number of predicate pathways, or quadratic to the
number of permitted predicates). In our experiments, the 43,954
example pairs were processed in around 5 min.
3.2.2. Results and discussion
The results of this study are shown in Table 2, which shows the
number of times each of the 10 most popular predicate-pathways
were most strongly associated with one of the 43,954 example
pairs. In addition, an illustrative example of each of the predicate
pathways is provided. Examples were selected on the basis of
our ability to interpret them, and represent one possible applica-
tion of the predication pathway concerned only. In some cases,
such as when the ‘‘COEXISTS_WITH’’ predicate is involved, patterns
are quite ﬂexible, as this predicate is extracted from sentences with
a broad range of meanings, including statements that drugs were
used together in combination, descriptions of commonly comorbid
conditions and structural similarity between entities. In each in-
stance, we retrieved a bridging or ‘‘B’’ term from the SemRep data-
base. Having identiﬁed the concepts and predicates involved, this
can be accomplished efﬁciently by triangulating the search.
Five of the ‘‘discovered’’ discovery patterns can be interpreted
as generalizations of the may_disrupt pattern designed by Ahlers
and her colleagues. In most cases, generalization occurs by relaxing
the constraint that the predicate linking the pharmaceutical sub-
stance to the bridging concept must be ‘‘INHIBITS’’, allowing
‘‘INTERACTS_WITH’’ and ‘‘STIMULATES’’ as alternatives. In addition
four of the other discovery patterns involve the predicate ‘‘COEX-
ISTS_WITH’’. In some cases, these involve linking a drug to a dis-
ease via a side effect of this drug. While this may be a reasonable
thing to do in the case that these side effects are produced by an
excessive action on the same pathway involved in the therapeutic
effects concerned, at times this inference may indicate that many
patients on the drug experience side effects of the drug. This latter
case is unlikely to lead to discovery. However, in general, the most
popular predicate pathways are readily interpretable, and their
application for the purpose of literature-based discovery seems
intuitive.
Fig. 3 provides an overview of the popularity of the 100 most
popular pathways. As is evident from the graph, a relatively small
number of the 272 possible dual-predicate pathways are most
strongly associated with most of the TREATS relationships in our
data set. As it is probable that TREATS relationships occur for which
no dual-predicate pathway exists that leads from the pharmaceu-
tical substance to the disease or syndrome concerned, we should
not assume that an accurate mapping was obtained in all cases.
The most strongly associated predicate path in such cases would
be an artifact of random overlap between random vectors. How-
ever, random overlap alone would result in an equal distribution
of popularity across dual-predicate pathways, while it is clear from
the ﬁgure that certain pathways are strongly associated with far
greater frequency than others. As illustrated on the ﬁgure, amongst
the thirty most popular pathways are the pathways ‘‘drug x INHIB-
ITS substance y; substance y ASSOCIATED with disease Z’’; ‘‘drug x
Table 2
Ten most popular predicate pathways. Pathways labeled ‘‘MD’’ generalize a component, or are a component, of the ‘‘may_disrupt’’ (MD) discovery pattern.
Predicate path Pairs Example and Comment
COEXISTS_WITH
ASSOCIATED_WITH
MD
7954 Heparin,_low-molecular-weight COEXISTS_WITH thrombin ASSOCIATED_WITH antiphospholipid syndrome.
COEXISTS_WITH here indicates changes in thrombin in the presence of low molecular-weight heparin. As such, this pattern can is a
generalization of MD
INTERACTS_WITH
ASSOCIATED_WITH
MD
6053 Pegvisomant INTERACTS_WITH somatotropin ASSOCIATED_WITH acromegaly This pattern generalizes the
‘‘INHIBITS:ASSOCIATED_WITH’’ component of the ‘‘may_disrupt’’ discovery pattern. Elevated somatotropin (or growth hormone) is
a deﬁning characteristic of acromegaly, so drugs interacting with it may be plausible treatments
CAUSES COEXISTS_WITH 2339 Dopaminergic_agents CAUSES dyskinetic_syndrome COEXISTS_WITH parkinsonian_disorders. This pattern relates drug
to disease via a side effect. This can occur as an epiphenomenon (many patients are treated these drugs, so we see these side effects
in them), or on account of superﬂuous effects on pathophysiologically relevant systems
INHIBITS ASSOCIATED_WITH
MD
2338 Crestor INHIBITS ldl_cholesterol_lipoproteins ASSOCIATED_WITH hypercholesterolemia,_familial. This plausible
pathway is part of the MD discovery pattern, and reveals the lipoprotein that crestor targets in treatment of hypercholesterolemia
STIMULATESASSOCIATED_WITH
MD
1146 Isobutyramide STIMULATES gamma-globin ASSOCIATED_WITH beta_thalassemia. Isobutyramide has been shown to
reduce transfusion requirements in patients with beta-thalassemia, and its activation of gamma-globin transcription provides a
plausible explanatory hypothesis for this observation, as levels of this globin are reduced in beta-thalassemia
INTERACTS_WITH CAUSES
MD
1001 Finasteride INTERACTS_WITH testosterone CAUSES prostatic_hypertrophy. This pattern is a generalization of the MD
pattern, and here correctly suggests that ﬁnasteride’s therapeutic effect in prostatic hypertrophy is due to interaction with
testosterone
PREDISPOSES COEXISTS_WITH 750 Proton pump inhibitors PREDISPOSES malignant neoplasm of stomach COEXISTS_WITH hiatal hernia. This instance of
this pattern links proton pump inhibitors (PPIs) to a premalignant condition of the esophagus via the link between extended use of
these drugs and an increased predisposition toward stomach cancer
INTERACTS_WITH PREDISPOSES
MD
653 Pravastatin INTERACTS_WITH plasminogen activator inhibitor 1 PREDISPOSES coronary heart disease. This pattern links
drugs affecting genes to diseases predisposed to by those genes
INTERACTS_WITH
COEXISTS_WITH
650 Emollients INTERACTS_WITH psoriasis COEXISTS_WITH eczema. In this instance, a treatment is linked to a disease via it’s
therapeutic effect on a commonly comorbid disease
COEXISTS_WITH AUGMENTS 560 Vardenaﬁl COEXISTS_WITH cyclic_gmp AUGMENTS erectile dysfunction. In this case COEXISTS_WITH was extracted from a
sentence indicating structural similarity between vardenaﬁl and cyclic_gmp, and AUGMENTS here indicates improvement
Fig. 3. Popularity of dual-predicate pathways.
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INHIBITS substance y’’; ‘‘substance y PREDISPOSES disease z’’.
These are the predicate pathways that make up that ‘‘may_disrupt’’
discovery pattern designed by Ahlers and her colleagues [4].
In the experiment that follows we attempt to apply the 10 most
popular predicate pathways to the problem of identifying agents
that treat cancers of various sorts.3.3. Generalizing explanatory hypotheses
In this experiment we evaluate the extent to which the discov-
ery patterns identiﬁed during our previous study can mediate the
identiﬁcation of ‘‘TREATS’’ relations between pharmaceutical
substances (UMLS type ‘‘phsu’’) and neoplastic processes (UMLS
type ‘‘neop’’). In order to accomplish this we created a PSI space
1056 T. Cohen et al. / Journal of Biomedical Informatics 45 (2012) 1049–1065ignorant of any direct relations between concepts of these seman-
tic types. We then constructed a test set of neoplastic processes,
and used the ‘‘discovered’’ discovery patterns to guide search
through these spaces using two different approaches that will be
described in the sections that follow. To provide a baseline, in addi-
tion to comparing PSI-based models to random selection of phar-
maceutical agents, we created a space capturing general
relatedness between concepts from the same set of titles and ab-
stracts using Reﬂective Random Indexing (RRI), a technique that
we have used effectively to simulate aspects of literature-based
discovery in previous research [23], [15].3.3.1. Methods
3.3.1.1. Model construction and test set. Fig. 4 provides an overview
of the methods and experimental design. A PSI space with the
same parameters as those employed in the previous study
was created from SemRep predications that met the following
constraints:Fig. 4. Experime1. Does not involve a pharmaceutical substance (UMLS type
‘‘phsu’’) and a neoplastic process (UMLS type ‘‘neop’’).
2. Both concepts involved have a global frequency <100,000
3. Predicate is part of the set {ASSOCIATED_WITH; COEX-
ISTS_WITH; AFFECTS; AUGMENTS; CAUSES; DISRUPTS; INHIB-
ITS; INTERACTS_WITH; PREDISPOSES; STIMULATES}.
3.3.1.2. Reﬂective random indexing. Reﬂective Random Indexing is
an iterative approach that is able to derive meaningful indirect
associations between terms or concepts from their distributional
statistics, without the scalability constraints imposed by computa-
tionally demanding alternatives [23]. One RRI space was created
from all documents in the set of citations (titles and abstracts)
from which the predication database was derived (n = 8,182,882)
that did not include both a ‘‘phsu’’ and a ‘‘neop’’ concept. Another,
which we will refer to as RRI_ALL, was derived from all documents
in this set without this constraint. Both were derived from the
MetaMap [38] output for these documents, which consists of thental design.
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output is embedded within the output of the SemRep system,
which draws on these concepts to extract predications. Conse-
quently, the RRI model had access to the collocated concepts from
which the predication database was derived, as well as those con-
cepts extracted by MetaMap that were not a part of predications
extracted by SemRep. Documents that contained a UMLS concept
of both the semantic type ‘‘phsu’’ and the semantic type ‘‘neop’’
were excluded, to ensure that the RRI model, like the PSI model,
is ignorant of any direct connections between concepts falling into
this category.
To ensure that differences observed occur on account of the
introduction of typed relations in PSI, we used a binary vector
implementation of RRI. Each represented concept was assigned
two binary vectors, an elemental vector and a semantic vector,
each of 32,000 dimensions. As was the case with our PSI imple-
mentation, elemental vectors were constructed by randomly
assigning 1s and 0s such that there was approximately a 0.5
probability of each occurring in any given dimension, and the ran-
dom number generator was seeded deterministically as described
previously to ensure that incidental overlap between elemental
vectors was consistent across models. Elemental vectors were
superposed using the majority rule to obtain semantic vectors,
with training occurring in the following sequence of steps:
RRI step one: generate document vectors
For each document:
For each concept in document:
S(document)+ = E(concept)  lw  gw
where:
lw = log(1 + frequency of concept in document)
gw = entropy(concept)
entropy ¼ 1þ R pij log2ðpijÞlog2ðnÞ
pij ¼ cfijgfi
cfij = frequency of concept i in document j
gfi = frequency of concept i in corpus
For each semantic document vector:
Normalize (majority rule)
RRI step two: generate semantic concept vectors
For each concept:
For each document concept occurs:
S(concept)+ = S(document)
For each semantic concept vector:
Normalize (majority rule)In order to ensure fair comparison between the two models, a
test set was constructed. This included all of the concepts catego-
rized as neoplastic processes (UMLS semantic type ‘‘neop’’) that
were represented in both models, which would require the concept
concerned meeting the global frequency threshold of <100,000 in
both spaces, and occurring in a predication that met the con-
straints of the PSI space detailed in the prior paragraph. In addition,
only neoplastic processes that occurred in at least one TREATS rela-
tionship with a pharmaceutical substance represented in both
spaces were included. The resulting test set consisted of 1,145
UMLS concepts categorized as neoplastic processes. Similarly, the
set of pharmaceutical substances in which treatments were sought
was constrained to concepts represented in both models, resulting
in a set of 16,269 pharmaceutical substances in which to attempt
to rediscover TREATS relationships extracted by SemRep from the
biomedical literature. We also retained the randomly constructedelemental vectors used to generate the RRI space, to approximate
the random selection of pharmaceutical substances as an addi-
tional control.
3.3.1.3. Approach to search across pathways. In addition to compar-
ing PSI and RRI, we compared two different approaches to search-
ing across the predicate pathways identiﬁed in the study, using
either the ﬁve or the 10 most popular predicate pathways. In the
ﬁrst of these, which we will denote ‘‘MAX’’, pharmaceutical sub-
stances are scored according to the strongest association to the dis-
ease in question across any single pathway. So, for example, if we
were considering only the pathways ‘‘INHIBITS:ASSOCI-
ATED_WITH’’ and ‘‘INHIBITS:CAUSES’’, the score of a pharmaceuti-
cal substance (phsu) for a neoplastic process in question (neop)
would be:
SCOREðphsuÞ¼MAXðSIMai;SIMacÞwhere
SIMai¼SIMðSðneopÞEðASSOCIATEDWITHÞEðINHIBITSÞ;SðphsuÞÞ
SIMac¼SIMðSðneopÞEðASSOCIATEDWITHÞEðCAUSESÞ;SðphsuÞ
where SIM = 1-normalized Hamming Distance.
That is to say, the score is the maximum score across any of the
predicate pathways. A disadvantage of this approach is that it con-
siders individual predicate pathways only (although these may in-
volve a number of different middle terms). However, one might
anticipate a pharmaceutical substance being meaningfully con-
nected to a disease that it treats through multiple predicate path-
ways. Therefore, rather than considering the maximum similarity,
it would seem pertinent to consider a measure of similarity that
considers the set of popular predicate pathways as a whole. We
use for this purpose an approximation of the span of vectors, de-
scribed as the quantum disjunction operator by Birkhoff and von
Neumann [39], and applied to information retrieval by Widdows
and Peters [40]. This operator measures the proportion of a vector
that can be projected onto a subspace derived from a set of compo-
nent vectors. The continuous implementation of this operator is
applied as follows:
1. An orthonormal subspace is constructed from the individual
vectors using the Gram-Schmidt orthogonalization procedure
[41]. That is to say, each vector in the set is rendered orthogonal
to every other vector in the set, such that no information is rep-
resented redundantly, and each vector is normalized to unit
length.
2. The individual vector v is projected into this subspace, to gener-
ate m^.
3. The cosine metric is used to calculate the similarity between the
vector v, and m^, it’s projection in the subspace.
This procedure can be interpreted as measuring the proportion
of the vector v that can be represented in the subspace, and will re-
turn a value of close to one if v is either similar to any individual
vector from which the subspace was derived, or partially similar
to several of the vectors from which this space was derived. For
our research, as our underlying representation is a hyperdimen-
sional binary vector rather than a real or complex vector, we devel-
oped a binary approximation of the quantum disjunction operator
we have just described [42].
The intuition underlying this operator is that maximal dissimi-
larity between a pair of vectors in the binary space will result in a
Hamming distance of half of the dimensionality of the vectors con-
cerned. Therefore, the extent to which the Hamming distance be-
tween two vectors is less than d/2 is analogous to the proportion
of one vector that could be projected onto another in continuous
(real or complex) vector space. We utilize a binary approximation
of the Gram–Schmidt procedure, through which binary vectors are
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introducing or eliminating identical dimensions at random. We
then calculate the similarity between an individual binary vector
and the set of (mutually orthogonal) vectors representing the pop-
ular predicate pathways to a neoplastic process (neop) by taking
the sum of 2  (0.5 – the normalized Hamming distance) between
the vector representing the pharmaceutical substance (phsu) and
each of these pathway vectors. So our approximation of the sub-
space-based metric, which we will denote SUB, considering only
the pathways ‘‘INHIBITS:ASSOCIATED_WITH’’ and ‘‘INHIB-
ITS:CAUSES’’, would be calculated as follows:
SCOREðphsuÞ ¼ 2
 ð0:5 HDðSðphsuÞ; SðneopÞ EðASSOCIATED WITHÞ  EðINHIBITSÞÞ
þ 0:5 HDðSðphsuÞ; SðneopÞ EðASSOCIATED WITHÞ  EðCAUSESÞÞÞ
where HD = the normalized Hamming Distance.
For each of the 1145 neoplastic processes, the PSI representa-
tions of the 16,269 pharmaceutical substances were searched using
both of these approaches, with either the 5 or the 10-most popular
predicate pathways identiﬁed during our previous studies. In addi-
tion, the RRI representations of the pharmaceutical substances
were searched using the RRI representation of the neoplastic pro-
cess concerned as a cue. Finally, elemental vectors for the pharma-
ceutical substances were searched using the elemental vectors of
the neoplastic processes as cues. This last step simulates random
selection of drugs for each disease, allowing for associations intro-
duced by incidental overlap between elemental vectors.
In all cases, the experiment was repeated at different statistical
thresholds, which were deﬁned in terms of the mean and standard
deviation of the anticipated Hamming distance between randomly
constructed elemental vectors. The thresholds used varied some
frommodel to model, as they were adjusted such that models were
compared according to the number of TREATS relationships ‘‘redis-
covered’’ when comparable quantities of pharmaceutical sub-
stances were suggested.3.3.2. Results and discussion
The results of this experiment are shown in Fig. 5, which plots
the number of rediscovered treatments (left axis) and proportion
of the total TREATS relationships rediscovered (or recall, right axis)Fig. 5. Overall rediscovery/recall. The y axes show the total number of rediscovered treat
number of treatments suggested per test case.for each model against mean number of pharmaceutical sub-
stances retrieved at different statistical thresholds.
The random model does not ‘‘rediscover’’ many therapeutic
relationships unless a large number of pharmaceutical agents are
retrieved. In contrast, the RRI-based model, here denoted ‘‘RRI’’ is
far more productive, recovering around two thousand TREATS rela-
tionships with a recall of around 0.17 at frequency thresholds that
return approximately 100 pharmaceutical substances on average.
The results for two RRI-based models are shown. In the ﬁrst, doc-
uments that included both a pharmaceutical substance (‘‘phsu’’)
and a neoplastic process (‘‘neop’’) were excluded from the training
process, as described previously. The second model, RRI_ALL differs
from the RRI model in that the entire corpus was utilized, including
those citations from which the test set was derived. The results for
SUB10 (not pictured) were close to, but below those obtained with
SUB5, which was the most productive of all the models tested,
recovering around 4500 TREATS relationships with a recall of
around 0.37 at a frequency threshold returning approximately
100 pharmaceutical substances on average. Interestingly, the SUB
models also outperformed RRI_ALL across all but the most strin-
gent thresholds. That is to say, the SUB models showed an advan-
tage over RRI trained on the entire set of documents processed by
SemRep, including those containing the statements fromwhich the
TREATS relationships in the test set were derived. This was not the
case with the MAX models with more stringent thresholds, which
serves as further evidence of the beneﬁt of the subspace-based ap-
proach. The MAX models, based on the single most strongly asso-
ciated predicate pathway, generally outperform the RRI model,
except at the most stringent statistical thresholds. A small advan-
tage over the MAX10 model (not pictured) occurs when only the
ﬁve most popular predicate pathways are utilized (MAX5, pic-
tured). The SUB models perform best of all, recovering thousands
of TREATS relationships even at the most stringent statistical
thresholds utilized. The model generally performs best when the
ﬁve most popular predicate paths are utilized (SUB5), except at
most stringent thresholds where using the 10 most popular pred-
icate paths appears to confer a slight advantage. With respect to
precision (Fig. 6), the subspace-based approaches again outper-
formed RRI-based and MAX approaches at most frequency thresh-
olds, although RRI_ALL and RRI had highest precision at the most
stringent thresholds, where the MAX models performed relativelyments for all test cases (left) and the global recall (right). The x axis shows the mean
Fig. 6. Overall precision. The y axis shows the precision and the x axis shows the mean number of treatments suggested per test case.
Table 3
Pearson’s correlation between AP and existing TREATS relationships.
SUB5 SUB10 MAX5 MAX10 RRI RRI_ALL RAND
r 0.5114 0.5085 0.4994 0.5602 0.0352 0.0423 0.1807
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are retrieved, the precision of the SUB5 model is around 0.38, sug-
gesting that we might anticipate rediscovering approximately four
known treatments per one hundred drugs retrieved. This number
of agents is of interest as it could feasibly be tested against cancer
cell lines using contemporary high-throughput screening methods,
and the successful repurposing of four therapeutically active com-
pounds in a hundred would be an excellent result.
When interpreting these results one should bear in mind: (a)
the fact that a drug does not occur in a TREATS relationship with
a particular condition in the SemRep database does not preclude
its being a plausible treatment; (b) a few TREATS relationship
may be SemRep errors; and (c) some TREATS relationships may re-
fer to activity against cell lines or animal models relevant to a par-
ticular cancer rather than proven therapeutic activity in the
context of a clinical trial. Nonetheless, evaluations have shown that
around 75% of the predications extracted by SemRep are accurate
so the results show that the incorporation of discovery patterns en-
hances the recovery of drugs with possible therapeutic activity
against the cancers concerned.
The results presented above report the overall recall and preci-
sion across the entire test set. The use of a global statistical thresh-
old allows for each model to suggest a different number of
treatments for each cancer, based on the strength of association
between this cancer type and each of the pharmaceutical sub-
stances in the search space. As the number of TREATS relationships
for each cancer in the set varies considerably (mean = 10.46,
std = 24.12, min = 1, max = 289, median = 3), there is an advantage
for methods that retrieve results selectively where treatments are
likely to occur, as would be expected from the predication-based
approaches in which treatments that are linked across one of the
predicate pathways would be more strongly associated. In order
to evaluate this hypothesis, we calculated the average precision
for each model for each cancer in the test set. The Average Preci-
sion (AP) [43] is a widely used summary statistic in information re-
trieval, and measures the precision at each point at which each
correct result is retrieved. This can be calculated by adding the pre-
cision at the point of each discovery (which is equal to the known
TREATS relations (rediscoveries) retrieved over the number results
retrieved) as follows:APðcaÞ ¼
Xn
i¼1
rediscoveries
rank
Consequently the average precision provides a summary of the per-
formance related to a particular cancer across all of the relevant
TREATS relationships in the test set. The correlation between the
average precision for each method and the number of TREATS
relationships available for discovery is shown in Table 3. As antici-
pated, the performance of the PSI-based methods is better corre-
lated with the number of treatments available for discovery than
that of the RRI-based methods.
The number of treatments available for discovery for a particu-
lar cancer is strongly correlated (Pearson’s r = 0.8473) with the
number of unique predications involving this cancer in the predi-
cation database. So PSI-based methods perform better where more
knowledge is available, which is not surprising.
Table 4 shows the mean and median rank of recovered treat-
ments for each model across all of the 11,972 treatments available
for discovery. Higher ranks (i.e. lower numbers) are preferable. For
example a rank of one would indicate that a treatment was the ﬁrst
result retrieved. Therefore, with higher average rediscovery rank as
a metric, the rank order of the performance of the models is
SUB5 > SUB10 > MAX5 > MAX10 > RRI_ALL > RRI > RAND. All dif-
ferences in average rank are statistically signiﬁcant as measured
by the paired t test (for the mean) and Wilcoxon’s signed rank test
(for the median). As shown in the last two rows of the table, which
give the percentage of all discoveries ranked in the top 100 and top
1000 results, the rank distributions for models other than RAND
are skewed to the right, with around 20% of the rediscoveries by
the SUB models ranked in the top 100.
The enhanced performance of the SUB5 model is also evident
when weighting the results for each cancer in the test set equally,
although the picture is more nuanced. Table 5 shows the Mean and
Table 4
Summary statistics for discovery rank. All differences in median rank are signiﬁcant as measured by Wilcoxon’s signed rank test. All differences in mean rank are signiﬁcant as
measured by paired t test. Boldface indicates best performance.
SUB5 SUB10 MAX5 MAX10 RRI RRI_ALL RAND
Mean 2559.5 2647.4 2828.3 2897.4 4305 3497 10162.5
Median 742 915.5 1021.5 1078 2866 1838 10108.5
Rank 6100 20.5% 19.5% 11.1% 10.8% 14.4% 19.7% 0.48%
Rank 61000 55% 51.34% 49.6% 48.6% 31.9% 40.7% 4.9%
Table 5
Mean and median average precision scores. Boldface indicates best performance.
SUB5 SUB10 MAX5 MAX10 RRI RRI_ALL RAND
Mean AP 0.0255 0.0247 0.0115 0.0108 0.0845 0.1097 0.0012
Rank 3 4 5 6 2 1 7
Median AP 0.0027 0.0021 0.0023 0.0021 0.0022 0.0086 0.0003
Rank 2 4 3 4 6 1 7
Table 6
Comparison of Average Precision (AP) scores. Proportion of Cases in which AP for Row Method was Greater than Column Method t+ indicates a signiﬁcantly greater row mean
than column mean by paired t test w+ indicates a signiﬁcantly greater row median than column median by Wilcoxon’s signed rank test. Boldface indicates a greater proportion of
row cases than column cases had greater AP.
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measure. Note that the means and medians give different rank
orderings for the methods. This discrepancy between mean and
median AP can be explained by the presence of a relatively small
number of outliers in the RRI results with AP > 0.5. On account of
these outliers, the median AP gives a more robust measure of over-
all performance than the mean AP.
Table 6 compares summary statistics for AP across all methods
evaluated. Each cell in the table compares the proportion of the
1145 neoplastic processes for which the method in the row had
a greater AP than the method in the column. In addition, the table
indicates cases in which the mean and/or median AP for the meth-
od in the row was signiﬁcantly higher than that of the method in
the column. So, for example, the cell [SUB5, MAX5] shows that
SUB5 had a higher AP than MAX5 around 70% of the cases, that
the difference between their median AP (SUB5 = 0.0027 >
MAX5 = 0.0023) is signiﬁcant as measured by the Wilcoxon signed
rank test, and that the difference between their mean AP
(SUB5 = 0.0255 > MAX5 = 0.0115) is signiﬁcant as measured by
paired t test. In contrast, the cell [MAX5, SUB5] shows that MAX5
had a higher AP in the remaining ±30% of cases. In general the tests
using medians favor the SUB5 model, although this advantage is
less pronounced than when considering the results from a per-dis-
covery perspective. It does not outperform RRI-ALL in this respect,
but that model enjoys access to information withheld from the
other models.
In summary, PSI-basedmodels, in particular the SUBmodels, re-
cover more total TREATS relationships at all but the most stringent
statistical thresholds applied. This corresponds to lower average
retrieval rank across all treatments available for discovery in thetest set, with statistically signiﬁcant differences in performance
by this metric across models such that SUB5 > SUB10 > MAX5 >
MAX10 > RRI_ALL > RRI > RAND. Analysis of average precision on
a per-disease basis reveals that the performance of PSI-based
methods is correlated with the number of TREATS relationships
available for discovery, which is in turn correlated with the amount
of knowledge related to this disease in the predication database. So
the advantage in performance when weighting each disease
equally is less pronounced than when considering the results from
a per-discovery perspective.
The performance of the SUBmodels suggests that effective ther-
apeutic agents tend to be connected to diseases they treat across
more than one predicate pathway. This supports recent criticism
of targeted drug discovery efforts as being inappropriately unidi-
mensional [44]. To illustrate the encoded connections that underlie
this ﬁnding, we reconstruct the pathways between multiple mye-
loma and thalidomide, which account for this therapeutic relation-
ship (an oft-cited example of successful drug repurposing) being
‘‘rediscovered’’ consistently, even at the most stringent statistical
thresholds applied to the SUB models (it is the 14th-ranked recom-
mendation in the SUB10 model, and 38th-ranked recommendation
in the SUB5 model). The pathways were reconstructed by search-
ing the original predication index for middle terms that relate to
both thalidomide and multiple myeloma in accordance with the
constraints imposed by the two most popular predicate pathways
from the original study, ASSOCIATED_WITH:COEXISTS_WITH and
INTERACTS_WITH:ASSOCIATED_WITH. As the binding operator in
our implementation commutes and is its own inverse, middle
terms that reverse the order of the relationships concerned, in this
case COEXISTS_WITH:ASSOCIATED_WITH, would also contribute
Fig. 7. Predicate pathways and bridging terms linking thalidomide to multiple myeloma considering the two most popular pathways only.
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been included. Only middle terms that were encoded in the PSI
space were retrieved, and middle terms of UMLS semantic type
‘‘phsu’’1 or ‘‘neop’’ were excluded, as predications linking these to
multiple myeloma and thalidomide respectively would not have
been encoded on account of the constraints placed during generation
of the space.
The pathways illustrated in Fig. 7 include biological entities that
interact with thalidomide and are associated with multiple myelo-
ma, and relationships between thalidomide and related diseases,
such as consequences of the overproduction of immunoglobulins,
that occur in multiple myeloma. While uninformative high-level
concepts such as ‘‘complication’’ and ‘‘dna’’ are included in the dia-
gram for completeness, these would have had less inﬂuence on the
relevant vector representations on account of the use of global
weighting statistics. Together, these two most popular predicatepathways account for 54 of the 143 unique predication pathways
(all predicate + middle term combinations within the constraints
of the 10 most popular pathways) that were encoded linking tha-
lidomide with multiple myeloma during the process of model con-
struction. With the SUB10 model, the number of unique
predication pathways relating multiple myeloma to its top 20
ranked pharmaceutical substances was consistently on the order
of 100, with a mean of 442.75 and a median of 413.5. These statis-
tics are summarized in Fig. 8 and support the proposal that the PSI
approach provides a computationally efﬁcient way of searching
across large networks of interconnected biological entities, as these
networks are encoded into hyperdimensional vector representa-
tions that can be compared to one another without the need to
consider their components individually.
The ﬁgure shows the top 20 results in rank order from left to
right, as well as the mean number of predication pathways in each
Fig. 8. Predication pathways supporting the top twenty ranked results for multiple myeloma (SUB10 model).
Table 7
Summary of Plausibility of Top 20 Results with Selected References.
Recommendation Interpretation
Immunoglobulins Intravenous immunoglobulins have been evaluated as prophylactic therapy in hypogammaglobulinemic patients with
lymphoproliferative disorders such as multiple myeloma [45]
Human leukocyte interferon Human leukocyte interferon has been shown to have in vitro effects and multiple myeloma cell lines [46] and has been proposed
as a therapeutic alternative in patients that do not tolerate therapy with other interferons
Interferon type ii This interferon, also known as interferon gamma, is known to produce Beta cell activating factor, an important cell survival
factor expressed by haematopoeitic cells [47]
Curcumina Curcumin analogs have been shown to suppress the growth of multiple myeloma cells in vitro [48]
Dinoprostone The cyclic AMP (cAMP) pathway, which is stimulated by dinoprostone (also known as prostaglandin E2) has been identiﬁed as a
possible therapeutic target for multiple myeloma, as elevated cAMP kills multiple myeloma cells in vitro [49]
Adriamycin Adriamycin (doxorubicin) is a component of standard treatment regimes for multiple myeloma (e.g. [50])
Dexamethasonea Dexamethasone has been evaluated as maintenance therapy for multiple myeloma [51]
Recombinant vascular endothelial
growth factora
Vascular endothelial growth factor is targeted by the anti-neoplastic agent Bevacizumab, which has been shown to inhibit the
growth of multiple myeloma cells [52]
Angiotensin ii Inhibition of angiotensin ii has been shown to augment the anti-tumor activity of other drugs in hepatocellular carcinoma.
Mechanisms of action appears to include inhibition of angiogenesis, and down-regulation vascular endothelial growth factor
[53].
pd_98059 pd_98059 is a MAP kinase inhibitor, and the MAP kinase pathway has been identiﬁed as a new therapeutic target for multiple
myeloma [54]
Genistein Genistein has been shown to inhibit the growth of multiple myeloma cells in vitro [55]
Serine We were unable to identify a potential therapeutic role for this amino acid
Pentoxifylline Pentoxifylline (Trental) has been shown to inhibit leukemic and lymphoma cells in vitro [56]
Thalidomidea Thalidomide has been shown to be effective in clinical trials against advanced multiple myeloma [57]
Zinc Zinc-alpha-2-glycoprotein is a biomarker that predicts responsiveness to thalidomide-based therapy in multiple myeloma [58]
Aldosterone Suppression of aldosterone has been shown to suppress the growth of hepatocellular carcinoma. The mechanism is related to
the inhibition of angiogenesis, which is an important therapeutic mechanism in multiple myeloma [57]
Quercetin Quercetin has been shown to induce multiple myeloma cell death at high doses [59]
Rituximaba Rituximab has been used to treat Acquired factor VIII inhibitor, a rare disorder that occurs in multiple myeloma patients [60]
ly294002 Ly294002 is an inhibitor of phosphoinositide 3-kinases (PI3ks). These kinases have been shown to be important for proliferation
of multiple myeloma cell lines[61]
Adenovirus vaccine Adenoviral-mediated gene transfer has been shown to cause growth suppression and cytotoxicity of multiple myeloma cells
in vitro [62]
a Occurrence in a TREATS relationship with multiple myeloma.
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support the prediction, and in one case this number exceeds
1000. The ﬁgure also shows the breakdown of these unique pred-
icate pathways in accordance with the popular predicate pathway
involved. Of interest, in this case the highest ranking results are
generally connected across all 10 of the popular predicate path-
ways we identiﬁed in our study, albeit with different distributions.The four most popular predicate pathways in these results all per-
mitted predications of the form ‘‘drug x INTERACTS WITH biological
entity y’’.
While similar numbers of predication pathways were found to
support several other predictions we examined, it was not always
the case that the entire spectrum of popular predicate paths was
represented. In addition, less frequently occurring concepts that
T. Cohen et al. / Journal of Biomedical Informatics 45 (2012) 1049–1065 1063were highly ranked were linked to the disease in question by fewer
predication pathways. At times a pharmaceutical substance that
occurred infrequently in the database would obtain a high ranking
on account of a substantial proportion of the predications it occurs
in in the database being connected to the disease in question in
accordance with the popular predicate pathways. This is what we
would anticipate, given that the tallying of the voting record across
superposition operations ensures that the relative contribution of
predications encoded into a semantic vector is of greater impor-
tance than the absolute number of predications processed. How-
ever, as our inspection of our results suggests that this may lead
to erroneous high ranking for agents about which little knowledge
is available, it seems likely that the addition of a minimum fre-
quency threshold could improve results.
This evaluation compares the ability of these models to
recover known TREATS relationships. However, it is also probable
that during the course of the evaluation the system recovers
hitherto unknown therapeutic relationships. Therefore, we
evaluated a small set of our experimental results to determine
the plausibility of a set of highly ranked results, only some of
which occurred in known TREATS relationships. Author PD,
who is a pharmacologist with expertise in cancer-related drug
discovery, conducted an independent evaluation of the twenty
top-ranked results produced by the SUB10 model. All of the
results with the exception of the amino acid ‘‘serine’’ and the
biomarker ‘‘zinc’’ were found to have citations that would justify
their potential as treatments of either multiple myeloma, or
problems such as hypogammaglobulinemia that afﬂict patients
with multiple myeloma. A summary of this review with selected
references is included in Table 7.4. Implications
In the research presented in this paper, we have used an ap-
proach based on the hyperdimensional computing paradigm[28],
in which both concepts and the relations between them are repre-
sented as vectors in hyperdimensional space. This approach is used
to implement efﬁcient inference across tens of millions of asser-
tions, using geometric operators. In our experiments, conducted
on a Linux workstation with 24G of RAM, inferring the most
strongly connected dual-predicate path took around 800 ls
per search, and searching across the 16,269 pharmaceutical
substances took around 80 ms per search. When examined further,
highly ranked results were often linked to the disease in question
by hundreds of unique predication pathways, which would need
to be explored independently with conventional methods. The
subspace approach, which rewards those pharmaceutical agents
connected to the disease in question across multiple predicate
pathways, was found to enhance the recovery of TREATS
relationships.
PSI’s successful recovery of large numbers of TREATS relation-
ships suggests the utility of such geometrically supported ap-
proaches as the means to support efﬁcient inference at scale. The
use of VSAs to accomplish reasoning that would traditionally be
attempted using symbolic approaches is not in and itself novel.
In fact, the enhancement of connectionist models of cognition to
enable computation of this sort was one of the original motiva-
tions for the development of VSAs [33]. However, while this family
of representational approaches has been adopted by the cognitive
science community as a means to simulate individual cognition
(see for example [63–65]), their utility as means to support
approximate inference at scale has not been widely explored.
Therefore, from our perspective perhaps the most important impli-
cation of this research is that of the untapped potential of repre-
sentational approaches that combine the strengths of geometricand symbolic approaches as a means to support computational
intelligence at scale. In order to encourage the further develop-
ment of these approaches, we have released an implementation
of PSI [66] as a part of the open source semantic vectors package
[67,68].
With respect to literature-based discovery, our ﬁndings provide
strong support for the utility of the discovery pattern approach,
pioneered by Hristovski and his colleagues [2], as a means to con-
strain the search space for new therapeutic approaches. On a size-
able test set, search across predicate pathways outperformed
search based on co-occurrence alone in what to the best of our
knowledge is the ﬁrst large-scale comparative evaluation of dis-
covery pattern based vs. co-occurrence based approaches. These
evaluations were enabled by the computational convenience affor-
ded by the PSI approach. In addition, PSI provides the means to
‘‘discover’’ discovery patterns, by inferring these from known
TREATS relationships. This provides an alternative to the manual
generation of discovery patterns, a process that requires both do-
main expertise and detailed knowledge of the predications ex-
tracted by SemRep.
Ultimately, our goal is to develop tools that can enhance the
cognitive capacity of biomedical scientists by enabling them to
draw upon knowledge extracted from beyond the bounds of their
usual literature review in order to generate novel therapeutic
hypotheses. This represents a deliberate move on our part away
from the goal of fully automated knowledge discovery, and toward
the notion of a dynamic and interactive discovery system in which
the user is free to reﬁne the predictions made by a system in an
exploratory iterative process. Developments along these lines in-
clude Wilkowski’s discovery browsing approach [69], and the
EpiphaNet system for biomedical knowledge discovery [15]. The
methods developed in this research provide the means to support
efﬁcient yet highly customizable searches across large volumes of
extracted biomedical knowledge, and therefore are likely to be use-
ful as the means to facilitate dynamic and interactive exploration
of knowledge extracted from the breadth of the biomedical
literature.
In addition, our approach has implications for the repurposing
of existing drugs to identify new therapeutic approaches for inad-
equately treated diseases. The rapidly escalating cost of new drug
development coupled with the prolonged delay in bringing new
drugs to clinical application, limits the availability of new therapies
for many devastating diseases. One of the most efﬁcient strategies
for addressing this problem is the ‘‘repurposing’’ of existing drugs
for novel therapeutic applications. There are currently approxi-
mately 4000 drugs approved for use in humans and an additional
5000 investigational drugs registered for human use but not ap-
proved by regulatory agencies. These drugs represent a rich reser-
voir of potential therapeutics because much of the pharmacologic
and toxicologic information necessary for their clinical use has al-
ready been acquired. Brute force screening of all possible combina-
tions of approved drugs or investigational agents is logistically
impossible and needlessly inefﬁcient. Knowledge applicable to
the selection of agents, and combinations of agents, is accessible
in large biomedical literature databases, and other repositories.
While efforts have been undertaken to integrate this knowledge,
and present it in computable form, exhaustive exploration of this
knowledge is not currently feasible. In the research presented in
this paper, we utilize the techniques of hyperdimensional comput-
ing to mediate approximate reasoning across large volumes of bio-
medical knowledge in a scalable and efﬁcient manner. The
improved recovery of TREATS relationships achieved by this meth-
od, and the plausibility of the results we have evaluated to date,
suggest that this approach may provide the means to leverage
existing biomedical knowledge to support future drug reposition-
ing efforts.
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In this paper, we document an evaluation of the ability of differ-
ent distributional models to recover TREATS relationships ex-
tracted by SemRep from the biomedical literature, in order to
simulate discovery. Manual evaluation of a small number of our re-
sults suggests that in many instances, predicted relationships were
plausible despite their not being extracted by SemRep previously.
However, even in the cases where these relationships are new to
SemRep, they are not necessarily new to science. Without further
evaluation to establish their novelty, we would not argue that
these results necessarily constitute anything more than simulated
discoveries. Our results also highlight a number of challenges that
must be addressed if we are to realize the translational potential of
these methods. Our knowledge base currently includes individual
drug-treatment relations, though we know that drug combinations
best treat many illnesses. Further investigation of the nature of the
TREATS relationships extracted by SemRep reveals that the system
currently does not distinguish between effective treatments and
agents that are active against a cell line in in vitro experiments,
so the recovered TREATS relations do not necessarily represent
treatments that have advanced to clinical trials. Our knowledge
base does not include knowledge gleaned from high throughput
experiments, which has been shown to be of value for drug reposi-
tioning [44]. Also, our models account for dual predicate pathways
only. While this was a necessary step, VSAs support encoding of
nested relationships, to perform inference over longer pathways
[33]. In future work, we will address these challenges by enhancing
the breadth and granularity of the knowledge utilized and develop-
ing models that accommodate the interactions between multiple
agents. In addition, we will explore the utility of real and complex
vectors as alternative representations to support inference in PSI.
6. Conclusion
In the research presented in this paper, we leveraged efﬁcient
inference mediated by hyperdimensional representations for two
purposes. Firstly, we inferred previously unknown discovery pat-
terns, pathways of predicates from a drug to a treated disease, from
a large number of example pairs. Secondly, we utilized these in-
ferred patterns to guide the search through PSI space for treat-
ments for neoplastic processes. When compared to a co-
occurrence based approach, discovery pattern based models were
better able to recover a held-out set of ‘‘TREATS’’ relations for these
neoplastic processes. This advantage was further emphasized
when rewarding drugs that were connected to the neoplasms in
question across several of the discovered discovery patterns. These
results demonstrate the utility of geometric representational ap-
proaches as a means to draw inferences from large volumes of
knowledge efﬁciently. In addition, they provide strong support
for the value of discovery patterns as a means to support litera-
ture-based discovery.
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